Overview
1) What the company does: Advanced Medical Solutions (AMS) develops and manufactures advanced wound care products to improve patient outcomes in wound management. 2) How its products work: AMS uses research-driven technology to create dressings and other wound-care solutions that manage moisture, protect the wound, and support healing, with developments supported by ongoing R&D and collaborations. 3) How it differs from competitors: AMS has a long track record in wound care, a history of growth through strategic acquisitions and partnerships, and capitalized expansion via an IPO on the London Stock Exchange, which has helped it broaden its product portfolio and global reach. 4) The company's goal: To improve patient care by delivering effective, technology-based wound care solutions and expanding access to them worldwide.
Work here?Claim your company
Simplify's take
What believers are saying
- H1 2026 revenue rose 4% to £115.5 million, with adjusted EBITDA up 8%.
- Peters Surgical integration is on track, supporting direct sales and manufacturing synergies.
- Management expects full-year 2026 EBITDA in line with expectations despite shipping delays and destocking.
What critics are saying
- H1 2026 exceptional costs hit £12.4 million, and site closures run through March 2027.
- Net debt reached £60.3 million in June 2026, limiting flexibility before the takeover closes.
- HB Fuller deal completion in Q4 2026 creates existential integration risk for standalone AMS roles.
What makes Advanced Medical Solutions unique
- AMS combines surgical adhesives, wound care, and biomaterials under one platform.
- Its 2026 direct-sales expansion in Europe reduces dependence on partner order timing.
- H.B. Fuller’s pending acquisition validates AMS’s specialty medical-adhesives niche and global distribution reach.
Help us improve and share your feedback! Did you find this helpful?